PMDA drug package insert
ヴァイトラックビカプセル25mg
PMDA Prescription drug · バイエル薬品株式会社 · package insert Aug 18, 2026
Key facts
| Brand names | ヴァイトラックビカプセル25mg, ヴァイトラックビカプセル100mg, ヴァイトラックビ内用液20mg/mL |
|---|---|
| Nonproprietary names | ラロトレクチニブ硫酸塩 |
| Companies | 製造販売元／バイエル薬品株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤/トロポミオシン受容体キナーゼ阻害剤 |
| Therapeutic category codes | 874291 |
| YJ codes | 4291071M1029, 4291071M2025, 4291071S1028 |
| Approval numbers | 30300AMX00251000, 30300AMX00252000, 30300AMX00253000 |
| Package insert edition | 第11版 |
| Package insert date | Aug 18, 2026 |
| PMDA document key | 630004_4291071M1029_1 |
| PMDA company code | 630004 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: